Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mantle-cell lymphoma: classification and therapeutic implications

R I Fisher1

  • 1Division of Hematology/Oncology, Loyola University Cancer Center, Maywood, IL, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 1, 1996
PubMed
Summary

Mantle-cell lymphomas are classified into four subtypes. Aggressive subtypes like nodular, diffuse, and blastoid have a poor prognosis, while the mantle zone variant may have a more benign course, warranting further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same author

Stromal gene signatures in large-B-cell lymphomas.

The New England journal of medicine·2008

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Mantle-cell lymphoma (MCL) is a peripheral B-cell neoplasm with a distinct phenotype.
  • MCL is subtyped into four categories: mantle zone, nodular, diffuse, and blastoid.
  • The clinical course and classification of the mantle zone pattern remain subjects of debate.

Purpose of the Study:

  • To clarify the classification and clinical implications of mantle-cell lymphoma subtypes.
  • To differentiate the prognostic significance of the mantle zone variant versus other MCL subtypes.
  • To highlight the potential for novel therapies in mantle-zone lymphoma.

Main Methods:

  • Review of the Revised European-American Lymphoma Classification criteria for MCL.
  • Analysis of morphologic, immunologic, and genetic phenotypes of MCL subtypes.

Related Experiment Videos

  • Correlation of subtype classification with clinical outcomes, including proliferative rates and survival.

    • Main Results:

    • Mantle-cell lymphomas are categorized into four subtypes: mantle zone, nodular, diffuse, and blastoid.
    • Nodular, diffuse, and blastoid subtypes exhibit high proliferation (cyclin D1 overexpression) and short median survival, indicating aggressive lymphoma.
    • The mantle zone variant is generally considered to have a more benign clinical course compared to other subtypes.

    Conclusions:

    • Mantle-cell lymphomas require precise subtyping for accurate prognosis and treatment.
    • Aggressive MCL subtypes necessitate prompt and intensive therapeutic strategies.
    • Mantle-zone lymphoma patients may benefit from novel therapeutic approaches, such as purine analogs.